Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Large Growth in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 7,670,000 shares, a growth of 40.5% from the October 15th total of 5,460,000 shares. Based on an average daily volume of 31,930,000 shares, the short-interest ratio is currently 0.2 days. Approximately 5.6% of the company’s shares are short sold.

Tonix Pharmaceuticals Stock Down 6.4 %

Shares of Tonix Pharmaceuticals stock traded down $0.01 during trading on Friday, hitting $0.13. 10,509,191 shares of the stock were exchanged, compared to its average volume of 10,158,421. The firm’s 50-day moving average price is $0.15 and its 200 day moving average price is $1.44. The stock has a market cap of $17.99 million, a price-to-earnings ratio of 0.00 and a beta of 2.06. Tonix Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $22.14. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 158.64%. As a group, analysts forecast that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its holdings in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the period. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. 82.26% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TNXP has been the topic of a number of research analyst reports. Alliance Global Partners boosted their target price on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, July 22nd. StockNews.com assumed coverage on Tonix Pharmaceuticals in a research note on Wednesday. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.